CN115433248A - Novel amino acid derivative separation and identification in red ginseng and novel application thereof - Google Patents
Novel amino acid derivative separation and identification in red ginseng and novel application thereof Download PDFInfo
- Publication number
- CN115433248A CN115433248A CN202211225983.XA CN202211225983A CN115433248A CN 115433248 A CN115433248 A CN 115433248A CN 202211225983 A CN202211225983 A CN 202211225983A CN 115433248 A CN115433248 A CN 115433248A
- Authority
- CN
- China
- Prior art keywords
- compound
- amino acid
- hfg
- red ginseng
- novel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to the field of natural pharmaceutical chemistry, and particularly discloses separation and purification of a novel amino acid derivative compound in Red ginseng (Red ginseng) and a novel application of the novel amino acid derivative compound. The compound is subjected to structure identification by adopting an amino acid automatic analyzer, nuclear magnetic resonance and positive and negative ion mass spectrometry, the molecular formula and the structural formula of the compound are deduced, and the compound is finally named as histadin-glucoside (HFG). Further in vitro cell activity screening results show that HFG has a good protective effect on HUVECs cell damage induced by glucose, and can be applied to preparation of medicaments for protecting cardiovascular diseases.
Description
The technical field is as follows:
the invention belongs to the technical field of medicines, and particularly relates to a novel amino acid derivative in red ginseng and a separation and preparation method thereof.
Background art:
ginseng Radix Rubri (Ginseng Radix et Rhizoma Ruba) is dried root and rhizome of Panax Ginseng C.A.Mey. Of Araliaceae, which is a traditional Chinese medicine with long application history. Warm in nature, sweet in taste and slightly bitter in taste, has the effects of greatly invigorating primordial qi, recovering pulse, relieving depletion, benefiting qi and controlling blood, and is used for treating diseases such as asthenia, desire for depletion, cold limbs, slight pulse, qi failure to control blood, metrorrhagia and metrostaxis.
Ginseng, as one of the rare Chinese medicinal materials, is rich in various components, and has a series of changes in the steaming process, so that the components in Ginseng radix Rubri are diversified. It is noted that some of the amino acid components in many of the compounds produced undergo maillard reactions, mainly with reducing sugars, via aldol condensation reactions, via Amadori rearrangement. In 1996, professor Zheng Yinan found, separated and purified a brand new amino acid derivative-AFG (aryl-respiratory-glucose) and AF (aryl-respiratory-glucose) in red ginseng for the first time, and pointed out that the amino acid derivative is one of Maillard products formed by Maillard reaction in the ginseng processing process, and preliminarily revealed the diversity of non-saponin components in red ginseng.
At present, cardiovascular diseases are an important factor of health loss in various regions of the world, and more researches are devoted to searching for new and effective drugs which can be used for preventing and treating cardiovascular diseases. Based on the traditional efficacy of red ginseng, the cardiovascular protection effect of red ginseng has been widely studied, and the main monomer components AFG and ginsenosides Rb1, rg1 and the like have been proved to have the protection effect.
So far, according to the research reports on the chemical components of red ginseng, no research report on the compound histidine diglycoside is found.
The invention content is as follows:
the invention innovatively discovers and separates histidine-fructose-glucose (HFG), a derivative of histidine and maltose.
The compound, namely the histidine bisglycoside HFG, is preliminarily proved to have the cardiovascular protection effect.
The invention provides a compound in red ginseng and a method for separating the compound from red ginseng.
The invention firstly provides a novel compound, which is named as histidine diglycoside and has the molecular formula: c 18 H 29 N 3 O 12 The structural formula is as follows:
the method for separating the compound consists of the following steps:
A. extraction: weighing Ginseng radix Rubri powder (20 mesh sieve), extracting with 5 times of anhydrous alcohol (material-liquid ratio: g/mL) under stirring at room temperature for 12 hr (rotation speed 1000 rpm), repeating the extraction for three times, and discarding alcohol solution; extracting with 10 times of distilled water under stirring at room temperature for 8 hr (material-to-liquid ratio: g/mL, rotation speed 1000 rpm), repeating the extraction for five times, mixing extractive solutions, and concentrating at low temperature to small volume of about 10g/mL.
B. Removing sugar and saponin: precipitating with 80% ethanol/water solution, removing most sugar, removing alcohol from the supernatant, concentrating to small volume (about 10 g/mL), passing through macroporous resin, eluting with water, collecting water eluate, concentrating, and lyophilizing.
C. Dissolving the lyophilized powder in double distilled water (concentration: 1 g/mL), passing through Sephadex LH-20 column, eluting with double distilled water, collecting ninhydrin positive reaction part, concentrating, and lyophilizing.
D. Dissolving the freeze-dried powder in a glacial acetic acid aqueous solution with the volume ratio of 0.2% to obtain a solution with the concentration of 1g/mL, passing through a Bio-gel P-2 column, eluting with 0.2% glacial acetic acid with the flow rate of 0.3mL/min, collecting components with the Rf =0.18, and freeze-drying to obtain the compound HFG.
The invention further provides application of the compound in preparing a medicine for protecting cardiovascular diseases, in particular application in preparing a medicine for preventing, treating or improving diabetes-induced vascular injury.
As a preferred embodiment of the present invention, the vascular injury includes atherosclerosis, vascular rupture, vasospasm, vascular contusion, and vascular compression.
In a preferred embodiment of the present invention, the vessel rupture includes a complete vessel rupture or a partial vessel rupture.
The invention further provides a pharmaceutical composition, which optionally comprises more than one auxiliary material, wherein the auxiliary material comprises an excipient, and the excipient comprises any one or more of an adhesive, a filler and a lubricant.
Compared with the prior art, the invention has the beneficial effects that:
the invention separates a new amino acid glucoside compound HFG from red ginseng, and the compound has better protective effect on HUVECs cell damage induced by glucose, and lays a foundation for the development and utilization of medicaments for protecting cardiovascular diseases.
Description of the drawings:
FIG. 1 is an amino acid autoanalyzer spectrum of HFG according to the present invention
FIG. 2 is an HPLC-ELSD spectrum of HFG of the present invention
FIG. 3 shows HFGs of the invention 1 H-NMR spectrum
FIG. 4 shows HFGs of the invention 13 C-NMR spectrum
FIG. 5 shows HMBC spectra of HFG of the present invention
FIG. 6 is an HSQC spectrum of HFG of the present invention
FIG. 7 is an HR-ESI-MS spectrum of HFG of the present invention
FIG. 8 shows that HFG improves glucose-induced cell damage of HUVECs
FIG. 9 is a graph showing the effect of AFG on glucose-induced HUVECs cell damage
The specific implementation mode is as follows:
the separation and purification method of the present invention will be further illustrated with reference to the following specific examples, but the scope of the present invention is not limited thereto.
EXAMPLE 1 isolation of HFG, a Compound of the invention
The formula of the compound HFG of this example is as follows:
1. the method for separating and preparing the compound HFG comprises the following steps:
A. taking red ginseng powder (sieving with a 20-mesh sieve), extracting with 5 times of anhydrous ethanol (material-liquid ratio: g/mL) under stirring at normal temperature for 12h (rotation speed 1000 rpm), repeating the extraction for three times, and removing ethanol solution; extracting the rest precipitate with 10 times of distilled water at room temperature under stirring for 8 hr (rotation speed 1000 rpm), repeating the extraction for five times, centrifuging, mixing the extractive solutions, and concentrating at low temperature to obtain a smaller volume of red ginseng and liquid with a ratio of about 10g/mL.
B. And B, taking the extract concentrated solution obtained in the step A, precipitating with 80% ethanol/water solution in volume ratio, standing at the temperature of 4 ℃ for 24 hours, centrifuging, and keeping the supernatant to remove most of sugar. Removing alcohol from the supernatant, concentrating to small volume (volume ratio is about 10 g/mL), passing through NKA macroporous resin, eluting with water, collecting water eluate, concentrating, and lyophilizing.
C. And D, dissolving the freeze-dried powder obtained in the step B in double distilled water to obtain a solution of 1g/mL, passing the solution through a Sephadex LH-20 column, eluting the solution by double distilled water, analyzing the solution by TLC, collecting a ninhydrin positive reaction part, concentrating and freeze-drying the ninhydrin positive reaction part.
D. Dissolving the freeze-dried powder in a glacial acetic acid aqueous solution with the volume ratio of 0.2% to obtain a solution with the concentration of 1g/mL, passing through a Bio-gel P-2 column, eluting with 0.2% glacial acetic acid with the flow rate of 0.3mL/min, collecting components with the Rf =0.18, and freeze-drying to obtain the compound HFG.
The compound HFG is pale yellowish white solid, and is detected and analyzed by an L-8800 full-automatic amino acid analyzer, and the retention time of the absorption peak of the compound is 12.52min as shown in figure 1. The absorption peak retention time of the compound is 24.21min as detected by HPLC-ELSD as shown in FIG. 2.
2. The monomer compound is subjected to structural identification by using modern nuclear magnetic resonance technology and high-resolution mass spectrum HR-ESI-MS
As shown in FIGS. 1 to 7 and Table 1, according to HR-ESI-MS m/z:480.1813[ 2 ] M + H] + (calculated: 480.1785) and its molecular formula C was determined by NMR spectroscopy 18 H 29 N 3 O 12 . The compound structure is identified as formula (I).
Process for preparing HFG of the Compound of Table 1 1 H and 13 C-NMR(600/100MHZ，D 2 o) data (ppm)
Example 2 protective effect of HFG, a compound of the present invention, on glucose-induced HUVECs cell damage in human umbilical vein endothelial cells.
1. Pharmaceutical formulation
HFG was dissolved in DMEM high-glucose medium to give 1mM/mL mother liquor, which was diluted to a concentration of: 1.0. Mu.M/mL, 2.0. Mu.M/mL, 4.0. Mu.M/L, 8.0. Mu.M/mL. Analytically pure glucose was dissolved in DMEM high-sugar medium to 150 mM/mL. HFG is unstable in property, the preparation needs to be carried out on site, the whole process is finished under aseptic conditions, and a filtering membrane is needed for use.
And performing parallel experiment by using arginine diglycoside (AFG) which is the same as the specific component in the red ginseng, wherein the specific process is the same as the above.
2. Cell culture
HUVECs cells were grown in DMEM high-glucose medium containing 10% fetal bovine serum and at 5% CO 2 And carrying out adherent culture in an incubator with saturated humidity and 37 ℃, and taking cells in logarithmic growth phase for experiment.
3. MTT method for testing influence of HFG on cell viability
HUVECs cell line 1.5X 10 5 Inoculating the culture medium at the density of each/mL and a 96-well plate, incubating the culture medium for 24h, removing supernatant, respectively pre-dosing by using HFG and AFG with different concentrations, administering an equivalent DMEM high-sugar medium to a control group and a model group, incubating the culture medium for 24h, removing supernatant, modeling by using 150mM/mL glucose, administering an equivalent DMEM high-sugar medium to a control group, incubating the culture medium for 24h, adding 20 mu L of MTT solution (5 mg/mL) to each well under a light-shielding condition, incubating the culture medium for 3.5h, removing supernatant, adding 150 mu L of DMSO to each well, fully vibrating the plate, and measuring the absorbance (OD value) at 490nm by using an enzyme reader.
4. Data processing
Comparative analysis between groups of experimental data statistical analysis was performed using Mean standard deviation (Mean ± s.d.), one-way analysis of variance (ANOVA), with p <0.05 or p <0.01 statistically significant, and histogram analysis was performed using GraphPad Prism 9.0.0 software.
5. Results
The protective effect of HFG on glucose-induced HUVECs cell damage in human umbilical vein endothelial cells is shown in FIG. 8.MTT results showed that HFG doses at 1-2. Mu.M exhibited significant protection (p <0.05, p- <0.01). The results of the AFG group experiments are shown in FIG. 9.MTT results show that AFG has no obvious protective effect on HUVECs cell damage induced by high sugar.
Therefore, the HFG has better advantages in the aspect of the protective effect on the cell damage of HUVECs induced by glucose.
The invention has been described in detail with reference to the preferred embodiments and illustrative examples. It should be noted, however, that these specific embodiments are only illustrative of the present invention and do not limit the scope of the present invention in any way. Various modifications, equivalent substitutions and alterations can be made to the technical content and embodiments of the present invention without departing from the spirit and scope of the present invention, and these are within the scope of the present invention. The scope of the invention is defined by the appended claims.
Claims (9)
1. A compound is named as histidine bisglucoside, and the molecular formula of the compound is as follows: c 18 H 29 N 3 O 12 The structural formula is as follows:
2. a process for preparing a compound according to claim 1,
the method comprises the following steps:
A. pulverizing Ginseng radix Rubri, sieving with 20 mesh sieve, extracting with 5 times of anhydrous alcohol (material-liquid ratio: g/mL) under stirring at room temperature for 12 hr (rotation speed 1000 rpm), repeating the extraction for three times, and removing alcohol solution; stirring and extracting with 10 times of distilled water (material-to-liquid ratio: g/mL) at normal temperature for 8h (rotation speed 1000 rpm), repeating the step of extracting with distilled water five times, combining the extractive solutions, and concentrating under reduced pressure at room temperature to a smaller volume of about 10g/mL;
B. precipitating with 80% ethanol/water solution, removing ethanol from the supernatant, concentrating to small volume (about 10 g/mL), passing through macroporous resin, eluting with water, collecting water eluate, concentrating, and lyophilizing;
C. dissolving the lyophilized powder in double distilled water (concentration: 1 g/mL), passing through Sephadex LH-20 column, eluting with double distilled water, collecting ninhydrin positive reaction part, concentrating, and lyophilizing;
D. dissolving the freeze-dried powder in a glacial acetic acid aqueous solution (concentration: 1 g/mL) with the volume ratio of 0.2%, passing through a Bio-gel P-2 column, eluting with 0.2% glacial acetic acid, collecting Rf =0.18 components, and freeze-drying to obtain the compound histidine diglycoside.
3. The compound histidine bisglycoside as claimed in claim 1, which is a pale yellowish white solid, is unstable at room temperature, is easily decomposed by moisture absorption, and can be stored at-20 deg.C for a long period after sealing.
4. The compound histidine bisglycoside as claimed in claim 1, wherein the retention time of the absorption peak of the compound is 12.52min as determined by L-8800 automatic amino acid analyzer.
5. Use of a compound according to claim 1 for the manufacture of a medicament for the protection of cardiovascular diseases.
6. The use according to claim 5, wherein the use is in the manufacture of a medicament for the prevention, treatment or amelioration of diabetes-induced vascular damage.
7. The use of claim 6, wherein said vascular injury comprises atherosclerosis, vascular rupture, vasospasm, vascular contusion, and vascular compression.
8. The use of claim 7, wherein the vessel disruption comprises a complete vessel disruption or a partial vessel disruption.
9. A pharmaceutical composition, which contains the compound of claim 1, and optionally comprises more than one auxiliary material, wherein the auxiliary material comprises an excipient, and the excipient comprises any one or more of a binding agent, a filling agent and a lubricating agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211225983.XA CN115433248B (en) | 2022-10-09 | 2022-10-09 | Novel amino acid derivative separation and identification in red ginseng and novel application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211225983.XA CN115433248B (en) | 2022-10-09 | 2022-10-09 | Novel amino acid derivative separation and identification in red ginseng and novel application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115433248A true CN115433248A (en) | 2022-12-06 |
| CN115433248B CN115433248B (en) | 2023-04-11 |
Family
ID=84251709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211225983.XA Active CN115433248B (en) | 2022-10-09 | 2022-10-09 | Novel amino acid derivative separation and identification in red ginseng and novel application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115433248B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116082421A (en) * | 2022-10-09 | 2023-05-09 | 吉林农业大学 | Preparation method and application of compound histidine bisglycosidic HFG in ginseng |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104447892A (en) * | 2014-09-11 | 2015-03-25 | 郑毅男 | Arginine-fructosyl-glucose detection method and medical application thereof |
| CN107865886A (en) * | 2016-09-26 | 2018-04-03 | 河北以岭医药研究院有限公司 | Panaxan is preparing the application in protecting vascular endothelial cell medicine |
| CN109846896A (en) * | 2019-02-27 | 2019-06-07 | 贵州师范大学 | Hederagenin is preparing the application in anti-vascular endothelial cell inflammatory damage drug |
| CN111956634A (en) * | 2020-08-28 | 2020-11-20 | 陕西医药控股医药研究院有限公司 | Use of paeonol derivatives for protecting vascular endothelium |
| CN112724184A (en) * | 2021-02-02 | 2021-04-30 | 吉林农业大学 | Novel method for efficiently separating and preparing special compound arginine diglycoside AFG in ginseng |
| CN113491702A (en) * | 2021-05-29 | 2021-10-12 | 南京工业大学 | Application of crocin-1 and/or crocin-2' in preparation of medicines for reducing blood fat and protecting endothelial cells |
-
2022
- 2022-10-09 CN CN202211225983.XA patent/CN115433248B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104447892A (en) * | 2014-09-11 | 2015-03-25 | 郑毅男 | Arginine-fructosyl-glucose detection method and medical application thereof |
| CN107865886A (en) * | 2016-09-26 | 2018-04-03 | 河北以岭医药研究院有限公司 | Panaxan is preparing the application in protecting vascular endothelial cell medicine |
| CN109846896A (en) * | 2019-02-27 | 2019-06-07 | 贵州师范大学 | Hederagenin is preparing the application in anti-vascular endothelial cell inflammatory damage drug |
| CN111956634A (en) * | 2020-08-28 | 2020-11-20 | 陕西医药控股医药研究院有限公司 | Use of paeonol derivatives for protecting vascular endothelium |
| CN112724184A (en) * | 2021-02-02 | 2021-04-30 | 吉林农业大学 | Novel method for efficiently separating and preparing special compound arginine diglycoside AFG in ginseng |
| CN113491702A (en) * | 2021-05-29 | 2021-10-12 | 南京工业大学 | Application of crocin-1 and/or crocin-2' in preparation of medicines for reducing blood fat and protecting endothelial cells |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116082421A (en) * | 2022-10-09 | 2023-05-09 | 吉林农业大学 | Preparation method and application of compound histidine bisglycosidic HFG in ginseng |
| CN116082421B (en) * | 2022-10-09 | 2023-07-07 | 吉林农业大学 | Preparation method and application of compound histidine bisglycosidic HFG in ginseng |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115433248B (en) | 2023-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2480438C (en) | Novel use of the extract of processed ginseng and saponin isolated therefrom | |
| CN107029120B (en) | Preparation method of dendrobium and polygonatum sibiricum soft extract | |
| CN115433248B (en) | Novel amino acid derivative separation and identification in red ginseng and novel application thereof | |
| Shin et al. | Ultra high pressure extraction (UHPE) of ginsenosides from Korean Panax ginseng powder | |
| CN103127192A (en) | Preparation method for fresh ginseng extractive and application thereof in II-type diabetics | |
| CN111035666A (en) | Ginseng extract with high content of rare saponin, ginseng wine and ginseng oral liquid | |
| KR101341755B1 (en) | The effective isolation method of panaxadiol saponin fraction from ginseng using pectinase | |
| KR100706111B1 (en) | A ginseng preparation using vitamin c and process for thereof | |
| CN110893197A (en) | Panax notoginseng extract for treating gout and preparation method thereof | |
| CN112159451A (en) | Gynostemma pentaphylla saponin extract and preparation method thereof | |
| CN106690244B (en) | Preparation and application of novel sweet gynostemma pentaphylla sweetener | |
| CN111450173A (en) | Formula preparation method and application of gynostemma pentaphylla and white tea for preventing type 2 diabetes | |
| US6395308B1 (en) | Purified extract from Harpagophytum procumbens and/or Harpagophytum zeyheri dence | |
| CN1190098A (en) | Preparation, medicinal composition and application of grouped gensenoside | |
| CN107929544B (en) | Preparation method and application of mileanine part and monomer in bletilla plants | |
| CN108424469B (en) | Gorgon fruit kernel polysaccharide and separation and extraction method and application thereof | |
| CN115925761A (en) | Extraction method and application of polygonatum sibiricum oligosaccharide | |
| CN113694104B (en) | Traditional Chinese medicine composition with protection effect on chemical liver injury and liver regeneration promotion function, preparation method and application thereof | |
| CN109223739B (en) | Composition and preparation method and application thereof | |
| CN107513092B (en) | Malonyl ginsenoside Rb1Preparation method and medical application thereof | |
| CN1334267A (en) | Process for preparing total sanchinoside | |
| CN112826835B (en) | Method for extracting active substances in honey | |
| Cha et al. | Effect of white, taegeuk, and red ginseng root extracts on insulin-stimulated glucose uptake in muscle cells and proliferation of β-cells | |
| KR102106018B1 (en) | Method For Producing Steaming Ginseng Berry Fermented Extracts Having Preventive and Improving Effects of Liver Damage | |
| KR102611611B1 (en) | Pharmaceutical composition containing platycodin D extracted from Platycodon grandiflorum and a method of producting thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |